CytoDyn (CYDY) Gross Profit (2021)

CytoDyn's (CYDY) quarterly Gross Profit came in at $173000.0 in Q4 2021, up 332.5% on a QoQ basis from $40000.0 in Q3 2021.

CytoDyn (CYDY) Gross Profit (2021) Analysis & Trends

CytoDyn (CYDY) has 1 years of Gross Profit data on file, last reported at $173000.0 in Q4 2021.

Quarterly Gross Profit changed N/A year-over-year to $173000.0 in Q4 2021, while the trailing twelve-month figure through May 2022 was $213000.0 (changed N/A YoY) and the FY2022 annual result came in at $213000.0, changed N/A from the prior year.
Gross Profit climbed to $173000.0 in Q4 2021, from $40000.0 in the prior quarter.
In the past five years, Gross Profit ranged from a high of $173000.0 in Q4 2021 to a low of $40000.0 in Q3 2021.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	CytoDyn	258.01 Mn	258.01 Mn	-

Historic Data

Download Data

Date	Value
Nov 30, 2021	173,000.00
Nov 30, 2021	173,000.00
Aug 31, 2021	40,000.00
Aug 31, 2021	40,000.00